Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease

In advanced chronic liver disease (ACLD), deregulated hepatic necroinflammatory processes play a key role in the development of liver microvascular dysfunction, fibrogenesis, and increased hepatic vascular tone, resulting in progression of ACLD and portal hypertension. Given the current lack of an e...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of hepatology 2021-05, Vol.74 (5), p.1188-1199
Hauptverfasser:	Boyer-Diaz, Zoe, Aristu-Zabalza, Peio, Andrés-Rozas, María, Robert, Claude, Ortega-Ribera, Martí, Fernández-Iglesias, Anabel, Broqua, Pierre, Junien, Jean-Louis, Wettstein, Guillaume, Bosch, Jaime, Gracia-Sancho, Jordi
Format:	Artikel
Sprache:	eng
Schlagworte:	Agonists Animals Anti-Inflammatory Agents - pharmacology Antifibrotic Agents - pharmacology Antihypertensive Agents - pharmacology Ascites Benzothiazoles - pharmacology Bile ducts Blood flow Cell activation Cells, Cultured Cirrhosis Cytokines Disease Models, Animal Drug Evaluation, Preclinical Endothelial cells Fibrosis Hemodynamics Hepatic hemodynamic Hepatic microcirculation Hepatocytes Humans Hypertension Hypertension, Portal - drug therapy Hypertension, Portal - etiology Hypertension, Portal - metabolism Liver - drug effects Liver - pathology Liver cirrhosis Liver Cirrhosis - complications Liver Cirrhosis - drug therapy Liver Cirrhosis - metabolism Liver Cirrhosis - pathology Liver diseases Liver fibrosis Macrophages Microvasculature Patients Peroxisome proliferator-activated receptors Peroxisome Proliferator-Activated Receptors - agonists Phenotypes Portal Pressure - drug effects PPARs Public health Rats Rodents Sulfonamides - pharmacology Thioacetamide Vascular Resistance - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!